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Parity is associated with an expanded macrophage population in the
mammary gland
Abstract
Pregnancy is a well established protective factor against breast cancer. One explanation for protection is the
increased differentiation status of the parous epithelium. However, this does not explain the association of
parity with increased aggressiveness of breast cancers, particularly cancers that occur soon after pregnancy.
Because tumor aggressiveness can be influenced by the cell population that surrounds the mammary
epithelium, we examined the potential role of the immune system in establishing a long-term difference
between the mammary glands of primiparous and virgin animals. Specific mRNA levels, enzyme activities and
antigen expressing cells were quantified in primiparous and virgin mammary glands from Sprague-Dawley rats
in diestrous. Our results show that macrophages, but not neutrophils or B-cells, are specifically increased in
fully involuted glands compared with age-matched virgin mammary glands. Macrophages play a dual role in
tumor progression, both opposing and supporting the process. Our finding of an increased macrophage
population in the primiparous mammary gland could explain the dichotomy of the reported association of
parity with decreased breast cancer incidence and increased breast cancer aggressiveness.
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Abstract. Pregnancy is a well established protective factor
against breast cancer. One explanation for protection is the
increased differentiation status of the parous epithelium.
However, this does not explain the association of parity with
increased aggressiveness of breast cancers, particularly cancers
that occur soon after pregnancy. Because tumor aggressi-
veness can be influenced by the cell population that surrounds
the mammary epithelium, we examined the potential role of
the immune system in establishing a long-term difference
between the mammary glands of primiparous and virgin
animals. Specific mRNA levels, enzyme activities and antigen
expressing cells were quantified in primiparous and virgin
mammary glands from Sprague-Dawley rats in diestrous.
Our results show that macrophages, but not neutrophils or
B-cells, are specifically increased in fully involuted glands
compared with age-matched virgin mammary glands. Macro-
phages play a dual role in tumor progression, both opposing
and supporting the process. Our finding of an increased
macrophage population in the primiparous mammary gland
could explain the dichotomy of the reported association of
parity with decreased breast cancer incidence and increased
breast cancer aggressiveness.
Introduction
It is well established that parity conveys protection against
cancers of the breast and other reproductive tissues. This
correlation has been demonstrated in many studies using
rodent models and from epidemiological analyses of human
populations. Full-term pregnancy seems necessary for
protection against breast cancer (1,2). However, the age at
first parity affects both the premenopausal and postmeno-
pausal risk for breast cancer (3). A meta-analysis of the
compiled data from 47 epidemiological studies in 30 countries,
which included 50302 women with breast cancer and 96973
women without breast cancer, showed a 4.3% decrease in the
relative incidence of breast cancer for every 12 months of
breastfeeding in addition to a 7.0% decrease in breast cancer
risk for each birth (4). The study also showed that protection
from cancer obtained by breast feeding or pregnancy was the
same in developed and undeveloped countries. The authors
concluded that almost 70% of the increased protection
against breast cancer observed in parous females of developing
countries can be accounted for by the larger number of births
per female and the increased frequency of breast feeding by
these latter populations (4).
Although parity protects against the occurrence of breast
cancer, it is also positively associated with increased aggressi-
veness of breast cancer and decreased cancer survival rates
(5-9). Thus, the effect of reproductive status on breast cancer
is complex, with full-term pregnancy and lactation contri-
buting to decreased cancer incidence and increased tumor
aggressiveness.
A change in the differentiation state of the mammary
epithelium or another cell type has been suggested as the
reason for parity-induced protection against tumor incidence
(10) and increased p53 expression was proposed as the
mediator of this effect (11). However, an increased differen-
tiation status of the mammary epithelium does not explain
the increased incidence of aggressive tumors in parous
compared with nulliparous females.
Microarray analyses have identified a small group of
genes that remain elevated in the fully involuted mouse and
rat mammary gland (12,13). Although the two studies did not
produce the same list of upregulated genes, there was some
overlap. First, the two studies were in agreement that expres-
sion of the major milk protein genes (a sign of epithelial cell
differentiation) remained elevated after 26-28 days of invo-
lution. Second, both studies showed elevated expression of
several genes that are expressed exclusively or highly by
macrophages. Third, the expression of some genes associated
with inflammation and the immune response were elevated in
primiparous glands, particularly in the mouse study. The
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results of these studies suggest the interesting possibility that
a consequence of parity is an increase in size of the immune
cell population of the fully involuted mammary gland and
that these immune cells influence epithelial differentiation
status and tumor aggressiveness.
We evaluated the hypothesis that parity results in an
increase in number of one or more hematopoietic cell type in
the mammary gland using the diestrous rat as our model.
Comparing the mammary tissue of primiparous and virgin
animals we found, in the former, higher expression of genes
that are upregulated during the innate immune response. We
also found that primiparous glands contain a higher density
of macrophages than the virgin glands. These results are
consistent with the hypothesis that one contribution of parity
to protection against breast cancer is a specific increase in the
size of the mammary macrophage population in the involuted
breast. The larger number of macrophages should provide
more effective immune surveillance and decreased cancer
incidence in parous compared with nulliparous females.
M1 macrophages, which protect against cancer, can be
converted by tumor cells to M2 macrophages that are also
referred to as tumor-associated macrophages (TAMs).
Whereas M1 macrophages engulf tumor cells and protect
against the development of cancer, M2 macrophages are
believed to promote tumor progression by secreting growth
factors and proteases, promoting angiogenesis and suppres-
sing adaptive immunity (14). Because the parous mammary
gland contains a larger pool of macrophages that are available
for conversion to the M2 type it might be expected that
cancers in the parous mammary gland are more frequently
aggressive compared with those in the virgin breast. Thus,
our observation of a specific increase in the macrophage
population in parous mammary glands leads to an over-
arching hypothesis to explain the effect of parity on breast
cancer that includes the influence of the macrophage on
epithelial differentiation, immune surveillance and tumor
aggressiveness.
Materials and methods
Experimental animals and materials. Female Sprague-Dawley
rats were obtained from Harlan Company (Indianapolis, IN).
The rats were allowed to undergo a 21-day lactation period
after delivery. Rats were then allowed at least 28 days for
complete involution of the mammary gland before being
sacrificed. Virgin rats were sacrificed in the same week as
the primiparous rats. All rats (primiparous and virgin) were
sacrificed at approximately 135 days of age and on the second
day of diestrous, which was confirmed by vaginal smear.
All animals were housed and treated according to current
NIH guidelines. Animal care was provided by an animal
caretaker and an attending veterinarian. This research was
conducted in accordance with the standards set forth in the
NIH guide for the care and use of laboratory animals.
Animals were sacrificed with CO2 inhalation prior to removal
of tissues for the described studies. Prior approval was
obtained from the appropriate university Committee on
Animal Care for all procedures performed on the animals
used in these studies. Unless another source is identified, all
chemicals used were reagent grade or higher and purchased
from Sigma (St. Louis, MO) or Fisher (Fisher Scientific Inc.
Fair Lawn, NJ).
RNA extraction and Northern blots. Tissues were frozen
immediately in liquid nitrogen upon removal from the animal
and stored at -80˚C. Total RNA was isolated using TRIzol
Reagent (Invitrogen, Carlsbad, CA) following the manu-
facturer's instructions. Northern blots were performed as
previously described with 15 μg total RNA per lane (15).
The blots were hybridized with the following 32P-labeled
probes produced by using the Megaprime DNA labeling
system (Amersham Pharmacia Biotech, Little Chalfont,
Buckinghamshire, England) with the following templates:
Lcn2 (cDNA PCR product amplified by primers: AGTC
GTCGACGACCTAGTAGCTGTGGAAACCATG and
CCTAAAGCTTTCAGCCACACTCACCACCCA), SGP2
(EcoRI fragment from SGP-2 plasmid obtained from MD
Griswold, Washington State University), GAPDH probe
(XbaI-PstI fragment of the rGAPDH plasmid obtained from
JM Blanchard, Centre Paul Lamarque, France). Between
hybridizations, the membranes were stripped by boiling 2
consecutive times in 0.1 X SSC with 0.1% SDS for 3 min.
Data were obtained by exposure to a phosphorimager
(Molecular Dynamics, Sunnyvale, CA).
Quantitative RT-PCR. Reverse transcription was done as
described previously (16). Briefly, 1 μg total RNA was treated
with 1 unit DNase (Invitrogen) for 15 min. After de-activation
of the DNase, the reverse transcription was performed using
superscript II (Invitrogen) with the 18 mer oligo(dT) and
dNTP. The qPCR was done in an Opticon (MJ Research,
Waltham, MA) or a Mini Opticon (Bio-Rad Laboratories,
Hercules, CA) with FullVelocity™ QPCR Master Mix
(Stratagene, La Jolla, CA). The amount of each mRNA was
quantified by using a standard curve created from a series of
known dilutions of the amplified fragments. Values that were
outside the range of the standards were not included and the
affected samples were reanalyzed at dilutions to ensure that
the values were within the range of the standard curve. The
relative mRNA levels were calculated by normalizing the
value for each mRNA to the result for the amount of the
cyclophilin reference mRNA that had been quantified in the
same sample. Primers used in the experiments were: Lcn2,
sense: CAGGCCCAGGACTCAACTCAGAA, anti-sense:
AGCGGCTTTGTCTTTCTTTCTGGA; cyclophilin: sense:
TGTTCTTCGACATCACGGCTGAT, anti-sense: GGACTT
GCCACCAGTGCCATTA; Igf1 sense: GGCACTCTGCTT
GCTCACCTT, anti-sense: CGGAAGCAACACTCATCC
ACA; Lbp sense: CTTGGCGTGGTCACGAATGTAT, anti-
sense: GGAATGCCTGGAACAGGTTCA; SPP1 sense: ATG
AGTCCTTCACTGCCAGCAC, anti-sense: TCATCGGACT
CCTGGCTCTTC; Mmp12 sense: GGTCAAGATGGATGA
AGCGGTAT, anti-sense: TCGTAATGTCAGCCTCGC
CTT; Mpeg1 sense: AGTGATGGATGCCAAGTGTCCTA,
anti-sense: TTGGTGGCAACTTGGCTCAT; TGFß3 sense:
CTGTTGCGGAGAGAGTCCAACTT, anti-sense: GGTCA
TCTTCGTTGTCCACTCCT; Emr1 sense: TTTCCTTGCCT
GCTTCTTCT, anti-sense: CCTGTCTCCGTATTCAGCCA;
CD14 sense: TACCGACCATGAAGCTTATGCT, anti-
sense: GATTTGCTTCCGTGTCCACA; IL-6 sense: ACAG
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CCACTGCCTTCCCTACT, anti-sense: GAACTCCAGAAG
ACCAGAGCAGA.
Myeloperoxidase (MPO) assay. The MPO assay was
performed according to the method of Bradley with minor
modifications (17). Briefly, frozen tissues were weighed and
homogenized in 1 ml ice cold 0.5% HTAB, 50 mM potas-
sium phosphate, pH 6.0. Homogenized samples were lysed by
freeze-thaw and clarified by centrifugation. Samples (20 μl)
were assayed with an incubation time of 10 min followed by
measuring the absorbance (A) at 450 nm. The MPO activity
was calculated with the formula: [(A10 min - A0 min) x 0.0565] /
gram tissue = MPO/gram tissue (17).
Immunohistochemistry. A polyclonal antibody recognizing
the macrophage marker CD68 was used as the primary
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for
immunohistochemistry. Paraffin-embedded tissue sections
from 6 mammary glands of primiparous rats and 8 mammary
glands of virgin rats were deparaffinized and rehydrated.
Antigen retrieval was done by boiling the sections then
storing them at 95˚C in 10 mM Tris-EDTA, pH 9.0. Nova
Red (Vector Laboratory, Burlingame, CA) was used for
visualizing the streptavidin-biotin-conjugated horseradish
peroxidase. Sections were then counterstained with Shandon
hematoxylin (Fisher Scientific, Itasca, IL) to identify nuclei.
Sectioning and staining was done by the Veterinary Pathology
Services, Iowa State University.
Macrophages were counted in ten randomly selected
fields in each section, one section from each tissue sample.
The counting was done blind with the identity of each sample
only uncovered after the data had been collected. The total
number of macrophages from the ten fields of each section
was used as the data point for that tissue sample.
Statistics. The standard deviation for the quotient of the
primiparous and virgin groups was calculated based on the
standard deviation of each group (18). P-values were calcu-
lated by t-test. 
Results
Effects of parity on the expression of immune response-
associated genes by the mammary gland. A previous micro-
array comparison of the genes differentially expressed in
mammary glands of primiparous compared with virgin mice
identified a set of genes associated with macrophages that
were elevated in the primiparous mammary gland compared
with age-matched virgin mammary gland (12). However, the
tissues pooled for this study were not of a defined stage in
estrous and were done with the mouse, which has not been
commonly used as a model for parity-induced changes in
mammary gland tissue.
We investigated the differences in gene expression
between mammary glands of primiparous and virgin rats in
diestrous with an emphasis on genes expressed by macro-
phages (Table I). Many of the mRNAs tested in the rat tissues
were the same as those identified by the previous microarray
of mouse tissues. However, some additional mRNAs that are
selectively expressed by macrophages were also investigated.
The results showed that the levels of several mRNAs that are
expressed by macrophages were significantly elevated in the
primiparous mammary glands. These mRNAs included CD14
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Table I. Expression of genes in rat mammary gland after
weaning.
–––––––––––––––––––––––––––––––––––––––––––––––––
Gene P/V std p-value
–––––––––––––––––––––––––––––––––––––––––––––––––
ºEmr1 2.79 2.54 0.003*
SPP1 2.57 2.75 0.030*
IL-6 2.07 1.61 0.015*
ºMmp12 2.05 1.70 0.027*
ºMpeg1 1.95 1.37 0.010*
Lbp 1.90 1.50 0.017*
Lcn2 1.68 1.05 0.021*
CD14 1.52 0.92 0.042*
SGP-2 0.95 0.41 0.670
IGF-I 0.88 0.41 0.520
TGFß3 0.52 0.62 0.150
–––––––––––––––––––––––––––––––––––––––––––––––––
Total RNA from mammary glands of primiparous (P) and age
matched virgin (V) rats were analyzed by Northern blot (SGP-2)
and real-time RT-PCR (all others). mRNA of target genes were
normalized to the reference gene, which was GPDH (Northern
blots) or cyclophilin (real-time PCR) of the same sample. Fourteen
parous rats and 9 virgin rats were used to obtain the data. Compa-
rison was also made of the cyclophilin and GAPDH levels in parous
v. virgin glands in each experiment dataset contributing to this
table. In all cases there was no statistically significant difference
between primiparous and virgin glands in the reference gene as
determined by an unpaired Student's t-test. Genes expressed by
macrophages are in italics. *p<0.05; ºmacrophage specific genes.
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 1. Macrophage gene expression is higher in primiparous mammary
glands compared with in age-matched virgin glands. Total RNAs from
mammary glands of rats were analyzed by (A) qPCR for which the values
for the target mRNAs were normalized to the reference gene cyclophilin of
the same sample, or (B) Northern blot, for which that values for the target
mRNAs were normalized to the reference gene GPDH of the same sample.
Samples from 14 primiparous rats and 9 virgin rats were used to obtain the
data. In all cases there was no statistically significant difference between
primiparous and virgin glands in the reference gene. P, primiparous; V, age
matched virgin.
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antigen (CD14), interleukin-6 (IL-6), osteopontin (Spp1/Eta-1),
macrophage-specific matrix metalloproteinase (MMP)-12,
and macrophage expressed gene 1 (Mpeg1) (Fig. 1). We also
found higher expression of Lbp in primiparous mammary
gland, but we did not find significant differences in the
mRNAs levels for IGF-1, TGFß3 and SGP2, all of which were
previously reported to differ between the mouse primiparous
and virgin tissues. Thus, the consistent finding between this
study in the rat and the previous microarray study of the
mouse mammary gland was that many macrophage markers
increase with parity.
Macrophage markers, but not neutrophil or B-cell markers,
are elevated in primiparous compared with virgin mammary
glands. The population sizes of immune cells (neutrophils,
macrophage, B and T cells) increase in the early stages of
mammary gland involution (19-22). Our results from gene
expression studies that suggest an increase in the macrophage
population in the primiparous mammary gland might reflect
the retention of a certain proportion of all immune cells after
involution is completed. To determine which immune cell
types are selectively retained in the primiparous mammary
gland after the gland has completely involuted, we tested for
these cell populations using MPO activity (neutrophils), and
the gene markers Emr1 (macrophages), B220 (B cells) and
OX40 (T cells) (20,23,24). The result showed no differences
in the neutrophil and B cell markers between primiparous and
virgin mammary glands (Fig. 2). The expression of OX40
was not detectable in any sample (data not shown). By contrast
the expression of the macrophage marker, Emr1, was higher
in the primiparous compared to the virgin mammary glands
(p<0.01).
Macrophages are more numerous in primiparous compared
with age-matched virgin mammary glands. The observation
of elevated levels in primiparous glands of mRNAs that define
macrophages could be explained by an increase in expression
of these genes per cell or by an increase in the number of
cells in the tissue. To determine if the macrophage popula-
tion in primiparous glands is higher than in virgin glands we
performed immunohistochemistry to detect and quantify
macrophages. The results demonstrated that there were more
macrophages in the fully involuted mammary glands than in
the age-matched virgin glands (p<0.01) (Fig. 3).
Parity-induced changes in gene expression are specific for
the mammary gland. To examine the possibility that the
parity-induced changes in abundance of macrophage markers
in the mammary gland reflects a body-wide change in
macrophage content, we examined other tissues for similar
differences in level of gene expression. For these studies the
Lcn2 and Emr1 were chosen as the test genes and normalized
to cyclophilin to examine specific changes in gene expres-
sion. As seen in Fig. 4, the difference between primiparous
and virgin tissues in expression of Lcn2 and Emr1 was only
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Figure 2. Macrophage-specific elevation of hematopoietic cell markers in
primiparous mammary glands. Representative markers were tested to
determine the relative population densities of immune cells in the mammary
glands of primiparous rats and virgin rats. Real-time RT-PCR was used to
detect macrophage marker Emr1 and B cell marker B220. The results were
normalized to the level of cyclophilin in the same sample. Neutrophils were
detected by the MPO assay. The Emr1 data are the same dataset as summa-
rized for this mRNA in Fig. 1. The error bars show the standard error of the
mean. *p<0.05 as determined by an unpaired Student's t-test. Mac, macro-
phage; Neu, neutrophil; P, primiparous; V, age-matched virgin.
Figure 3. More macrophages are found in primiparous compared with virgin
mammary glands. (A) Immunohistochemical staining with anti-CD68 of a
paraffin-embedded tissue section from a rat mammary gland with x1000
magnification. The yellow scaling ruler, inserted by the microscope in the
bottom right corner, at the time of photography is 50 μm in length. (B)
Macrophages were counted from 10 randomly selected fields with x400
magnification of each section. The total number of macrophages in the ten
fields was used for analysis. Error bars are the standard error of the mean
from 6 primiparous samples and 8 virgin samples, respectively.
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observed in the mammary gland, thus showing that the effect
of parity is specific for this gland.
Discussion
The participation of inflammatory cells in mammary gland
involution has been reported in several studies in which the
results of microarray analysis and histochemical staining
indicated growth of the hematopoietic cell population, parti-
cularly neutrophils and macrophages, in the mammary gland
during involution (22,25,26). However, all these studies were
of mouse mammary glands at early stages of involution (up
to 4 days of involution).
Fully involuted mouse mammary glands showed higher
levels of gene expression markers for macrophages, B-lym-
phocytes and T-lymphocytes in the involuted compared with
the virgin glands (12). We also observed a difference in
expression of macrophage marker genes (Mpeg1, Mmp12)
between primiparous and virgin rat mammary glands, but did
not observe evidence of significant differences in B-cell
(B220) or neutrophil (MPO activity) populations. The
difference in expression of Lbp, Mmp12 and Spp1 between
primiparous and virgin glands was also observed in a recent
microarray study of rat mammary glands (13).
A consistent finding in our study and the microarray
analysis was of significant increases in the levels of expres-
sion of a number of markers for macrophages. From these
results we reasoned that a possible explanation for the
protective effect of parity against cancer is increased immune
surveillance in the parous breast. Therefore, we examined the
relative levels of markers for hematopoietic cells in involuted
and virgin mammary glands. Neutrophil populations in the
tissues were determined by the MPO assay (17,27) and
showed no difference between the primiparous and virgin
groups. Analysis by real-time RT-PCR of B220, a B-lympho-
cyte marker, also demonstrated no difference between the
two groups. Although microarray analysis found higher
levels of immunoglobulin gene expression after involution
compared with virgin mice (12,25) the results of immuno-
histochemical staining of a B-cell marker showed no obvious
changes in the B-cell number even in mammary glands at
early stages of involution (25). Taken together, these results
suggest that although the number of B-cells does not increase
in the mammary gland after involution is completed, some
immunoglobulin genes remain more active than in the virgin
gland.
We tested the levels of several mRNAs, namely IGF-I,
Lbp, Mmp12, Spp1, TGFß3 and SGP2, that showed altered
expression between involuted and virgin mammary glands of
mouse (12). Among them, Lbp, Mmp12 and Spp1 also showed
higher expression in a microarray analysis of primiparous
mammary glands of the rat (13). We also found higher
expression of Mmp12 and Spp1 in the fully involuted rat
mammary gland. We did not find differences in expression
levels of IGF-I, TGFß3 and SGP2 and these latter genes also
did not appear as up- or down-regulated in the rat microarray
study although they did differ between primiparous and
virgin gland in the mouse microarray. The difference in results
for these mRNAs could be due to the species difference or
to the immune status or other condition of the animals on
sacrifice.
The expression levels of several macrophage markers
[Mpeg1, Mmp12, CD14 and Emr1 (F4/80)] were higher in
the mammary glands of primiparous compared with virgin
rats. The mouse microarray study identified Mmp12 and
Mpeg1 (12) and the rat study identified Mmp12 (13). To
evaluate the macrophage population in the mammary gland,
we stained tissue sections for the macrophage marker, CD68,
and discovered that the macrophage density of the primi-
parous gland is higher than in the virgin mammary gland.
Although not supported by earlier studies (28,29) more recent
studies have shown that the number of macrophages in the
mammary gland increases during involution (25,30,31). Thus,
macrophages may enter the mammary gland during involution
and a subset remains in the gland for at least 28 days when the
rat mammary gland is considered to be fully involuted.
While parity protects against the occurrence of breast
cancer, it is also positively associated with increased aggressi-
veness of cancer and decreased survival rates (5-9). These
studies showed a large increase in cancer aggressiveness in
breast cancer of parous compared with nulliparous females
within ~6 years of parturition. Although most studies did not
show a measurable effect of parity on tumor aggressiveness
later in life, at least one study found an association of axillary
lymph node involvement with parity in women with 4 preg-
nancies or more and this association was strongest with older
women (7).
The association of parity with increased aggressiveness of
breast cancer could be explained by the presence of larger
numbers of macrophages in the mammary gland after partu-
rition because macrophages are capable of being converted
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Figure 4. Selective increase in macrophage gene expression in mammary
glands of the primiparous rat. Total RNA from liver, uterus, ovary and
mammary gland of rats were analyzed by real-time RT-PCR for Emr1 and
Lcn2. The values are the Emr1 or Lcn2 mRNA normalized to cyclophilin
mRNA of the same sample. The Emr1 and Lcn2 data for the mammary
gland are the same dataset as shown for these mRNAs in Fig. 1. P, primi-
parous; V, age matched virgin. Fourteen primiparous and 9 virgin rats were
used in the experiment. Error bars show the standard error of the mean.
*p<0.05.
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from the protective M1 macrophage to the tumor promoting
M2 macrophage. Macrophages remaining in the mammary
gland after pregnancy would contribute to creating a different
microenvironment in the tissue than is present in the virgin
gland. It has been argued that the reason for a higher frequency
of more aggressive cancers after pregnancy is that a wound
healing and inflammatory microenvironment is established in
the mammary gland during involution and that this micro-
environment is conducive to the proliferation of tumor cells
(32). The macrophage is a component of both wound healing
and inflammatory microenvironments and here we show that
it is the one immune cell type that is elevated in primiparous
compared with age-matched virgin rats.
Studies of the effects of hormonal treatments on the
susceptibility to breast cancer have lead to proposals that the
extent of differentiation of the epithelium in the parous
breasts is greater than in virgin breasts (10). This proposal
was supported by the finding that p53 is required to observe
the effect of parity on carcinogen-induced mammary gland
cancer (33,34). However, p53 was not amongst the genes
found to be differentially expressed in the primiparous
compared with the virgin mammary gland (12,13). Our finding
of an increased number of macrophages in the primiparous
gland is compatible with the previous hypothesis that epithelial
differentiation is more complete in the primiparous gland and
that p53 is required for differentiation to occur. However, we
propose that the driving force that protects against cancer is
the increased size of the mammary macrophage population.
Macrophages are known to be associated with the terminal end
buds and to promote differentiation of the mammary epithelium
(35,36).
During mammary gland involution, a local inflammatory
response occurs in the absence of infection (25,37). Lcn2 is
an acute phase protein (APP) with high expression in the
mammary gland and uterus during involution (15). Its expres-
sion level in the fully involuted mammary gland of primi-
parous rats is higher than in virgin rats. Lcn2 is expressed by
epithelial and hematopoietic cell types and induces apoptosis
in neutrophils but not in macrophages (38). The persistently
high expression of Lcn2 in involuted mammary gland may be
a reason that more macrophages but not neutrophils remain
after involution is complete. To test this hypothesis, we
compared the relative expression of macrophage marker,
Emr1, and Lcn2 in a variety of tissues of primiparous and
virgin animals and found that the expression of Emr1 is higher
in primiparous compared with virgin mammary glands, but
not in other reproductive tissues nor in liver. Lcn2 is highly
expressed in these tissues on toxic or endotoxin challenge
(liver) or during involution (uterus) or throughout the ovarian
cycle (ovary). The similar proportional expression patterns
of Emr1 and Lcn2 in primiparous compared with virgin
animals suggests a relationship but our studies do not reveal
more.
The increased Lcn2 might also reflect an increased
inflammatory microenvironment in the primiparous gland.
This was indicated by the increase in other acute phase
proteins, particularly in the mouse microarray study. An
increase in the expression of acute phase genes might also
reflect a low level of inflammation in the glands (or one of
the glands pooled for the microarrays) that is not associated
with parity. In our study this was not so. Whereas the level of
Lcn2 expression was higher in primiparous compared with
virgin mammary glands, the level of SGP-2, another acute
phase gene, was not different.
Parity also provides protection against endometrial cancer
and ovarian cancer in humans as it does for breast cancer
(39-45). We did not find evidence of more macrophages in
the rat uterus and ovary of primiparous compared with virgin
rats. This may imply that increased immune surveillance
provided by macrophages is not a universal protective factor
against cancer in different organs after parity and that it may
not be the only mechanism for protection. However, the lack
of evidence of protection against endometrial cancer and
ovarian cancer provided by parity in rats makes it difficult to
relate our results for these tissues to the results of studies of
endometrial and ovarian cancers in women.
Decreased Lcn2 expression has recently been reported to
suppress the formation of mammary gland cancer and its
metastasis in Lcn2-/- MMTV-Erb2(V664E) and MMTV-PyMT
transgenic mammary tumor mouse models (46,47). Our results
show a positive correlation between Lcn2 and macrophage
markers in the primiparous gland, which could indicate that
Lcn2 is involved in recruiting macrophages into the mammary
gland. Decreased macrophage recruitment to the mammary
gland results in decreased tumorigenesis and metastasis in
the MMTV-PyMT mouse model (48-50). Lcn2 can also
attenuate LPS-induced cytokine production in macrophages
(51), the latter being a classical response associated with M1
macrophages (52). This action of Lcn2 would move macro-
phages to the M2 phenotype and thus Lcn2 may facilitate the
conversion of macrophages from M1 to the M2 type that
promotes mammary gland tumorigenesis and metastasis.
Unlike the normal animal, the MMTV-PyMT and MMTV-
Erb2(V664E) mouse model contains cells in the mammary
gland that are predisposed to transformation. Thus, a change
in the balance of M1 to M2 macrophages might have a
proportionately larger effect on the expansion of cancer in
these glands compared with in the mammary glands in a
normal animal.
In summary, we have found that the number of macro-
phages is increased in involuted primiparous rat mammary
glands compared to age-matched virgin glands. We propose
that the resulting increased immune surveillance in the mam-
mary gland may play a role in the protective effect of parity
against breast cancer. Ironically, the higher frequency of
macrophages in the primiparous gland may also be responsible
for the observed positive association of parity and more
aggressive breast cancers.
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